Storia in 2 fonti

As China embraces AI, few US pharmaceutical execs bet on it for innovation

Survey finds drug companies planned to scale AI or had already done so, but few anticipated a ‘wholesale revolution’ from the tech.

Raccontata da

scmp.com

adexchanger.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

scmp.comStai leggendo2 g fa

As China embraces AI, few US pharmaceutical execs bet on it for innovation

72% of pharma companies scale AI in R&D, yet only 24% expect significant improvement in drug success. Speed gains won't convert to profit without solving human bottlenecks; clinical judgment remains a critical barrier regardless of AI.

originale

adexchanger.com16 h fa

Agentic AI Is Rewriting The Pharma Marketing Playbook | AdExchanger

AI is transforming how the pharma industry approaches drug development. On average, the industry invests $2.6 billion to bring a new treatment to market, taking 12 to 15 years with a 10% success rate. But pharma…

Leggi questa versione →

Timeline cronologica

mercoledì 9 settembre 2026·scmp.com
As China embraces AI, few US pharmaceutical execs bet on it for innovation
Survey finds drug companies planned to scale AI or had already done so, but few anticipated a ‘wholesale revolution’ from the tech.
giovedì 10 settembre 2026·adexchanger.com
Agentic AI Is Rewriting The Pharma Marketing Playbook | AdExchanger
AI is transforming how the pharma industry approaches drug development. On average, the industry invests $2.6 billion to bring a new treatment to market, taking 12 to 15 years…